Vornorexant (Synonyms: ORN-0829; TS-142)

Name: Vornorexant
Brand: MedChemExpress
SKU: HY-139559
Rating: 4.5 (1 reviews)

Cat. No.: HY-139559 Purity: 99.66%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia research research.

For research use only. We do not sell to patients.

Vornorexant Chemical Structure

CAS No. : 1517965-94-4

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 715	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 715	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1050	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 2100	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 3400	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 5500	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Orexin Receptor (OX Receptor) Isoform Specific Products:

View All Isoforms

OX₂ Receptor OX₁ Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

OX₂ Receptor

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	1.05 nM Compound: (-)-3h, ORN0829	Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincubated for 30 mins followed by orexin-A stimulation by Fluo4-AM dye based fluorescence analysis Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincubated for 30 mins followed by orexin-A stimulation by Fluo4-AM dye based fluorescence analysis	[PMID: 32482533]
CHO-K1	IC₅₀	1.27 nM Compound: (-)-3h, ORN0829	Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincubated for 30 mins followed by orexin-A stimulation by Fluo-4AM dye based fluorescence analysis Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincubated for 30 mins followed by orexin-A stimulation by Fluo-4AM dye based fluorescence analysis	[PMID: 32482533]

In Vivo

Vornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep^[1].
Vornorexant exhibits optimal PK properties with a rapid T_max and short half-lives in rats and dogs. The T_1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat^[1]
Dosage:	1, 3, 10 mg/kg
Administration:	Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg
Result:	Possessed promising sleep-inducing and sleep-promoting effects.

Clinical Trial

Molecular Weight

447.46

Formula

C₂₃H₂₂FN₇O₂

CAS No.

1517965-94-4

Appearance

Solid

Color

White to light yellow

SMILES

O=C(N1[C@@H](OCCC1)CN2N=C(C3=CC=C(C=N3)F)C=C2)C4=C(N5N=CC=N5)C=CC(C)=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (223.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2348 mL	11.1742 mL	22.3484 mL
5 mM	0.4470 mL	2.2348 mL	4.4697 mL
10 mM	0.2235 mL	1.1174 mL	2.2348 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.66%

Select Batch:

Data Sheet (274 KB) SDS (252 KB)

COA (251 KB) HNMR (370 KB) LCMS (264 KB) OR (236 KB)

Handling Instructions (2659 KB)

References

[1]. Aya Futamura, et al. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. Bioorg Med Chem. 2020 Jul 1;28(13):115489. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2348 mL	11.1742 mL	22.3484 mL	55.8709 mL
	5 mM	0.4470 mL	2.2348 mL	4.4697 mL	11.1742 mL
	10 mM	0.2235 mL	1.1174 mL	2.2348 mL	5.5871 mL
	15 mM	0.1490 mL	0.7449 mL	1.4899 mL	3.7247 mL
	20 mM	0.1117 mL	0.5587 mL	1.1174 mL	2.7935 mL
	25 mM	0.0894 mL	0.4470 mL	0.8939 mL	2.2348 mL
	30 mM	0.0745 mL	0.3725 mL	0.7449 mL	1.8624 mL
	40 mM	0.0559 mL	0.2794 mL	0.5587 mL	1.3968 mL
	50 mM	0.0447 mL	0.2235 mL	0.4470 mL	1.1174 mL
	60 mM	0.0372 mL	0.1862 mL	0.3725 mL	0.9312 mL
	80 mM	0.0279 mL	0.1397 mL	0.2794 mL	0.6984 mL
	100 mM	0.0223 mL	0.1117 mL	0.2235 mL	0.5587 mL

Vornorexant Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vornorexant1517965-94-4ORN-0829 TS-142ORN0829ORN 0829TS142TS 142TS-142Orexin Receptor (OX Receptor)Hypocretin ReceptorHCRT ReceptorinsomniaOX1ROX2Rsleep-promotingInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Vornorexant (Synonyms: ORN-0829; TS-142)

Customer Review

Vornorexant Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Orexin Receptor (OX Receptor) Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vornorexant Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report